(WASHINGTON, D.C.) – Today, President Trump announced new medications and partnerships through the TrumpRx platform. Following this news, David Marin, President and CEO of the Pharmaceutical Care Management Association, released the following statement:

“Expanding access to more affordable generics is critical to bringing down drug costs in America. We applaud the president’s continued focus on prescription drug affordability and his willingness to confront big brand drugmakers over their high prices. TrumpRx is providing more ways for patients without drug coverage to access medications, and we welcome this emphasis on generic medicines.

“Pharmacy benefit managers understand that drug competition is critical to making prescriptions more affordable, and we are proud that several of our companies have partnered with TrumpRx. Lawmakers in Congress should build on today’s announcement by helping get more generics to market sooner. We must crack down on the ways big drugmakers abuse the patent system to keep competition away and prices high. That will only make TrumpRx and all pharmacy benefits more affordable for patients who need them.”